NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Daniel C. Burke, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, has been appointed to the Plaintiffs' Executive Committee in the multidistrict litigation established earlier this year for all federally-filed product liability lawsuits involving Onglyza and Kombiglyze XR.
According to an Order issued by the U.S. District Court, Eastern District of Kentucky, on September 4th, Mr. Burke and his fellow committee members will work closely with Plaintiffs' Co-Lead and Liaison Counsel to coordinate case management of the proceeding. (IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION, MDL No. 2809)
"Our Firm is representing numerous clients who developed heart failure and other cardiovascular complications, allegedly as a result of exposure to saxagliptin, the active ingredient in Onglyza and Kombiglyze XR. We are pleased that Mr. Burke will be playing such an integral role in this litigation," says Sandy A. Liebhard, a founding partner at Bernstein Liebhard LLP.
The Firm continues to offer free legal reviews to individuals who were diagnosed with heart failure or other cardiovascular injuries following treatment with Onglyza or Kombiglyze XR.
Onglyza and Kombiglyze XR are indicated to lower blood sugar levels in patients with Type 2 diabetes. The U.S. Food & Drug Administration (FDA) approved Onglyza (saxagliptin) in 2009. Kombiglyze XR, (saxagliptin and metformin) was approved the following year.
In April 2016, the FDA ordered the manufacturers of Onglyza and Kombiglyze XR to add warnings regarding a potential risk of heart failure to the labels of all saxagliptin-containing Type 2 diabetes drugs. The agency acted after a clinical trial called SAVOR-TMI suggested that saxagliptin was associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality.
More than 200 Onglyza and Kombiglyze XR lawsuits are now pending in the federal multidistrict litigation underway in Kentucky. Plaintiffs involved in this proceeding claim that AstraZeneca and Bristol-Myers Squibb concealed information linking saxagliptin to an increased risk of heart failure and failed to warn doctors and patients about its alleged potential to cause cardiac arrest, congestive heart failure, and death.
Type 2 diabetics who developed heart failure or other serious cardiovascular complications allegedly related to their use of Onglyza or Kombiglyze XR could be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To contact an attorney and obtain a free case evaluation, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP